NCT Number: NCT00094640
Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
The goals of this study are to:
Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with Zyprexa (olanzapine) tablets or by intramuscular administration with Zyprexa IntraMuscular (olanzapine for injection).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–76 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Adelaide, South Australia, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients must have schizophrenia or schizoaffective disorders.
- Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent.
- Patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry.
- Female patients must not be pregnant or breast-feeding.
- Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or schizoaffective disorder.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Important dates
- First posted
- Oct 22, 2004
- Registry last updated
- Jul 19, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Personalized and Scalable Cognitive Remediation Approaches
NCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsGenetic Study of Schizophrenia
NCT00001486
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsFunctional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsSUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
NCT06007105
Acute and Transient Psychotic Disorder, Bipolar Type I Disorder With Psychotic Symptoms
Blantyre, Southern Region, Malawi
View Trial Details